PwC specialists unpack how regulatory changes, pricing pressures, and global innovation are influencing pharma and health services M&A—and what companies should do now to reassess pricing strategies, stabilize supply chains, and navigate policy risk.
Rewire your pharma supply chain strategy with three decisive actions you can take now—while navigating shifting policy landscapes and geopolitical changes.
How the One Big Beautiful Bill reshapes US healthcare and what providers, payors, PBMs and pharma should do to respond to policy, funding and coverage shifts.
Companies are responding with targeted mitigation strategies, while maintaining flexibility as tariff policies continue to evolve.
Health services M&A has weathered a complicated macroeconomic and political environment but, strong subsector growth demonstrates sector durability.
The health industries quarterly offers insights on accounting and reporting hot topics impacting the industry.
PwC specialists break down MFN drug pricing and what companies should do now to reassess pricing, supply chains, and policy risks.
This publication highlights industry-specific factors to be considered and provides guidance on the most pertinent accounting solutions for the pharmaceutical, life sciences and medical device industry.
Explore how pharma and biotech leaders can navigate FDA disruption with smarter submissions, regulatory agility, and global risk mitigation strategies.
Explore the rise of China’s biotech industry and what it means for U.S. pharma, from innovation and partnerships to diligence and global strategy.
Learn how hospitals can use reimbursement solutions for uncompensated care through Medicare bad debt reimbursement and hospital cost report strategies.
China’s biotech boom presents US pharma with both opportunity and risk. Biopharma leaders must reassess diligence, strategy and geopolitical exposure.
